AGP Executive Report

Autoimmune CAR-T Safety: Novartis and Bristol Myers Squibb paused multiple autoimmune CAR-T trials after safety concerns—Novartis reported fatal immune reactions in Rap-cel studies, while BMS halted Zola-cel enrollment after transient inflammatory events, with cancer trials still moving. Clinical Guidance Update: The American Academy of Neurology and American Headache Society released updated migraine prevention guidance for adults, replacing 2012 recommendations and outlining when to start and how to choose preventive meds. Gene Therapy Push: uniQure filed for FDA accelerated approval of its Huntington gene therapy ifezuntirgene inilparvovec (AMT-130), also submitting to the UK MHRA. Cardiac Imaging Standards: SCCT released updated CCTA recommendations aimed at more consistent reporting of plaque and stenosis, including expanded AI-related workflow guidance. Public Health & Equity: A major international JAMA Network Open review links intimate partner violence to higher child mortality, underscoring violence prevention as a health intervention. Workforce & Policy: Pennsylvania will audit home healthcare agencies after wage theft complaints surged, targeting overtime and pay violations. Health Tech & Research Capacity: Cleveland Clinic opened two major research buildings, adding 300,000 square feet for labs and core services.

EMS Policy Shift: Indiana ends routine ambulance diversions for crowded EDs, allowing diversions only for disasters or critical infrastructure failures. Radiology Payment Scrutiny: A JAMA Network Open study finds CMS devalues radiology services more often than radiology societies’ recommendations, raising concerns about how imaging is priced. Cardiometabolic Food Warning: Research presented at ESC links higher blood xylitol levels to greater major cardiovascular event risk, putting a spotlight on the sugar alcohol found in “sugar-free” gum and toothpaste. Mental Health Genetics: Scientists identify 36 genes tied to OCD and chronic tic disorders, pointing to new treatment targets. Regulatory Innovation in the UK: MHRA launches its first regional NHS “sandbox” in Manchester to speed testing of AI and software medical devices. Hormone Access & Safety: In Wales, women reportedly pose as men to buy testosterone online after prescription barriers, with clinicians warning about dangerously high hormone levels. Biotech & Patents: Purple Biotech gets a USPTO notice of allowance strengthening protection for its CAPTN-3 multispecific antibody platform. Biomanufacturing Capacity: South Korea’s biologics boom continues, but companies still rely on imported biomanufacturing materials. Patient Portal Load: JAMA reports patient portal messaging surged while clinician inboxes became a major workload driver.

Clinical Trial Breakthrough: A randomized trial found a single 10 mg oral hydrocortisone dose improved attention and verbal learning within hours in virally suppressed women with HIV, with daily dosing over four weeks linked to better delayed memory recall. Behavioral Health Funding: HHS/SAMHSA awarded $77M in new grants for substance use prevention, community mental health, suicide prevention, and crisis services. Long COVID Update: In the RECOVER-VITAL trial, extending Paxlovid to up to 25 days showed no clinical benefit for long-COVID cognitive, autonomic, or exercise intolerance symptoms. Drug Pricing Policy: The Trump administration added nine mid-size drugmakers to the Most Favored Nation program, alongside $19.6B in U.S. manufacturing commitments and an expanded active pharmaceutical ingredients reserve. Vaccine Pipeline: GSK advanced its dual-antigen mRNA seasonal flu vaccine into a first-of-its-kind Phase 3 trial after stronger immune responses in Phase 2. Rare Disease Data Access: Two Irish health tech startups are merging to help rare disease patients keep one continuous health and research record instead of losing data across providers and studies. Cancer Care: Enhertu plus Perjeta won EU approval as a new frontline option for unresectable or metastatic HER2-positive breast cancer.

Biotech Leadership & Funding: Immunophotonics closed a $10M Series C and promoted Robert H. Arch, Ph.D., to CEO as it advances IP-001 toward Phase 2 milestones. Medical Devices & Imaging: Profound Medical named Richard Fabian President, signaling continued push in interventional MRI. AI-Enabled Care Access: Rocket Doctor AI reported 43% Q2 revenue growth and a surge in completed U.S. visits after expanding in-network coverage to ~24M lives. Rare Disease & Equity: GeneDx CEO Katherine Stueland earned a 2026 Fierce 50 Health Equity honor, highlighting genomics-driven earlier diagnosis. Epilepsy Pipeline Update: Stoke Therapeutics and Biogen shared 4-year zorevunersen open-label results for Dravet syndrome at EEC, with Phase 3 EMPEROR ongoing. Public Health Guidance: WHO updated typhoid vaccine advice for earlier dosing (9–24 months) amid drug resistance. Policy & Cost Pressure: Trump announced expanded most-favored-nation drug pricing deals projected to save $600B, while KFF flagged a $1,200 breast MRI out-of-pocket bill despite coverage expectations. Care Delivery & Oversight: Radiology experts urged stricter rules around self-interpretation of imaging orders as utilization patterns appear linked to who reads scans. Global Health Capacity: CIDRZ handed over TB lab upgrades and equipment in Zambia to strengthen diagnosis and treatment.

Drug Pricing Push: Trump announced nine more “most-favored-nation” deals with mid-sized pharma, bringing participation to 26 companies and claiming coverage of 89% of branded drugs—aimed at lowering Medicaid prices and boosting U.S. access to newer medicines. Cancer Trial Updates: Final COMBI-I results show spartalizumab plus dabrafenib/trametinib improved overall survival in BRAF V600-mutant melanoma, with higher rates of fever and treatment-related side effects. Breast Cancer Care: New expert discussion highlights how second-line choices in HR+/HER2− metastatic breast cancer hinge on progression timing, disease burden, performance status, and repeat biomarker testing (including ctDNA and tissue reassessment). Cardiovascular Outcomes: VESALIUS-CV analysis reports evolocumab reduced all-cause death by 20% in high-risk patients without prior heart attack or stroke. HIV Treatment: FDA approved Bixlenvo as a once-daily complete switch regimen for virologically suppressed adults with HIV-1. Veterinary Safety: Revival Animal Health recalled certain feline milk replacers after tests found low essential vitamins and minerals for newborn kittens. Medical Tourism: South Korea saw foreign spending on medical services jump 66.5% in July, led by dermatology and plastic surgery. Care Delivery Innovation: A UNC telehealth rapid access prostate cancer program cut referral-to-biopsy time from 161 to 71 days.

Medical Tourism & Spending: South Korea’s foreign visitors spent 213 billion won ($145M) on medical services in July, up 66.5% year over year, with dermatology and plastic surgery still leading but pharmacy spending rising. Cell Therapy Funding: China’s Simnova Biotech raised about $59.5M to speed confirmatory studies for its off-the-shelf CAR-NK therapy and advance in vivo CAR-T work. Drug Access in Hong Kong: Hong Kong approved another new therapy under its “1+” mechanism for chronic spontaneous urticaria, bringing the total to 22. Diagnostics Expansion: Mahajan Imaging and Neuberg Diagnostics are teaming up to build an integrated diagnostics network across seven North Indian states, combining imaging, pathology, genomics and wellness. Cardiometabolic Breakthroughs: Plozasiran (RNAi targeting APOC3) cut triglycerides ~80% at 1 year and reduced acute pancreatitis events in SHASTA-3/4. Care Delivery & Safety: FDA warned patients about quality failures at a California mammography center, including delayed reports and severe image quality issues. Primary Prevention Push: England’s NHS pharmacies will start offering seven-minute cholesterol checks this autumn, with pharmacist-led follow-up for eligible patients. Healthcare Logistics: FedEx earned its 30th IATA CEIV Pharma certification, expanding global capability for temperature-controlled pharmaceutical shipments. AI in Clinical Workflows: A case report highlights risks when AI flags suspicious imaging findings without incorporating clinical context, urging safer integration practices.

AI in Primary Care: Patient.info launched “AskPatient,” a free UK AI symptom checker that pairs conversational help with its clinically reviewed library, aiming to guide users on next steps without diagnosing or prescribing. Cancer Care Standards: ASCO released its first living guideline for recurrent high-grade epithelial ovarian/fallopian tube/primary peritoneal cancer, outlining platinum-based options and biomarker-selected non-platinum sequencing. Pediatric Surgery Innovation: Ontario’s first paediatric scoliosis operation using the Medtronic Mazor robotic spine platform helped a teen achieve near-perfect correction with faster, more precise screw placement. Cardiology Trial Watch: EPIDAURUS was stopped early after potent P2Y12 inhibitors plus a DOAC increased bleeding without reducing ischemic events in AF patients with recent MI. Neurodegeneration Research: New findings link orexin levels to Alzheimer’s cognitive decline, with protective effects tied to stronger sleep spindles and NREM brainwaves. Public Health & Access: HHS is piloting a rapid, five-minute syphilis test for newborn protection, while UHN’s PSA Detect and Protect expands free prostate screening for high-risk Black men. Healthcare Operations: A UPMC/ KLAS report warns AI adoption is outpacing testing and governance, with fewer than half of hospitals running dedicated AI validation before patient-facing use.

Insulin Access Push: California’s CalRx program has distributed 120,000 five-pen packs of insulin glargine at $55 each, aiming to help uninsured patients and pressure big drugmakers as the state’s generic label rolls out slowly. Cardiology Drug Update: Results from the Phase 2b LUMINARA trial show oral relaxin agonist AZD5462 improved cardiac function in chronic heart failure, with findings presented at ESC 2026. Antibiotics in Kids: A randomized trial found azithromycin didn’t reduce wheezing severity in preschoolers in ERs, regardless of whether bacteria were present. Digital Health & Behavior: Experts say digital detoxes fade fast unless people change reward patterns, triggers, and routines—not just put phones away. Maternal Nutrition & Autism: A study of 80,000 mother-child pairs links healthier pregnancy diets with a 22% lower autism diagnosis rate, while stressing it’s an association, not proof of prevention. Medical Tourism Boom: South Korea saw 2.01 million foreign medical tourists in 2025 (+71.9%), and July spending rose 66.5% year over year, led by dermatology and plastic surgery. Healthcare Policy Scrutiny: A report estimates $65B was spent in 2024 on improper ACA and Medicaid enrollments, including duplicated or ineligible coverage.

AI in Oncology: Clinicians are being urged to test generative AI tools on real tumor-board cases while keeping humans in charge, with concerns raised about whether some retrieval-based systems meet privacy rules. Cardiovascular Prevention: Real-world MILOS data links 1 year of bempedoic acid therapy to lower predicted 10-year cardiovascular risk, extending trial findings into routine care. Regulatory Watch: The FDA granted fast-track status to an investigational LRRC15-targeting antibody-drug conjugate for soft tissue sarcoma, signaling faster development for a hard-to-treat cancer. Health Policy & Costs: Older Australians are weighing proposed changes to private health insurance rebates, with fears that more people will shift into an already strained public system. Care Access & Equity: In Edo State, community outreach and counseling are expanding family planning access, while patient experiences highlight gaps like limited pre-insertion testing. HIV & Aging: New discussion spotlights how HIV care has transformed over decades, with a growing share of people living with HIV now in older age groups. Clinical Practice: Guidance on chronic ear infections emphasizes that cleaning and proper canal management can be the difference between treatment working or failing. Pharma Industry: Aurobindo Pharma set up a new wholly owned overseas subsidiary to expand manufacturing and marketing. Public Health Systems: Delaware Health Information Network added a chief growth officer to broaden analytics and ecosystem services.

Cardiovascular Breakthroughs: ESC 2026 data spotlight evolocumab’s LDL-C gains right after MI (AMUNDSEN) and a VESALIUS-CV subanalysis showing a 36% cut in first MI risk across major subtypes, while PREMIUM reports prasugrel monotherapy after STEMI isn’t noninferior to 12 months of DAPT. Infection Care: POET-II finds response-tailored shorter antibiotics for left-sided infective endocarditis can cut treatment duration by about a third, with slightly higher relapse rates. Inflammation & Kidney Risk: TRANQUILITY shows pacibekitug (IL-6) delivers sustained hs-CRP drops in CKD patients at high inflammatory risk; STAT+ flags Novartis’ inflammation drug strategy as heart-outcome questions remain. Regulation & Tech: FDA opens public input on regulating generative AI medical devices, as healthcare leans harder into AI tools. Public Health Policy: India’s FSSAI proposes red front-of-pack warning labels for high sugar/salt/fat foods, but critics warn loopholes could blunt impact. Wellness & Lifestyle: A small study links 10 minutes of ultra-slow running to immediate mood and executive-function boosts; another finds sweeteners may affect reward-circuit changes differently than sugar.

Biomanufacturing Expansion: Argentine biosimilars maker Biosidus finished a $12.9M biomanufacturing upgrade, tripling cell culture capacity to support its Fabry disease agalsidase beta biosimilar and future international partnerships. Medicare Advantage Scrutiny: A new study finds Medicare Advantage enrollees with a new complex diagnosis are more likely to leave for traditional Medicare, raising concerns about access and plan switching barriers. COVID-19 Vaccines: FDA cleared updated COVID-19 shots, with guidance focused on older adults and people with higher-risk conditions, while healthy younger adults are urged to discuss risk with clinicians. Cardiometabolic Breakthrough: FDA approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes, showing an 8% lower rate of cardiovascular death, heart attack, or stroke vs Trulicity. HIV Treatment Update: FDA approved Gilead’s Bixlenvo, a once-daily single-tablet regimen for virologically suppressed HIV patients. Healthcare Policy & Access: CMS’s DMEPOS supplier enrollment moratorium ended Aug. 27, and the AHA urged CMS to avoid payment and enrollment changes that could increase reporting burdens and threaten beneficiary access. Public Health Gap: JAMA Network Open reports a sharp rise in never-screened cervical cancer rates among young U.S. women, with later-stage incidence increasing after 2017. AI in Care: Cleveland Clinic’s AI Summit highlighted how AI is entering clinical workflows, while local hospitals test tools to improve care and cut costs. R&D Funding Push: Philippines’ DOST proposed a 2027 budget emphasizing R&D and STEM, including major support for grants and research institutes.

Public Health Watch: PharmEasy’s Fever Watch says monsoon fever risk is now in its highest-risk weeks, with risk higher than early season across 186 of 209 cities; typhoid is driving most “HIGH” readings, with test positivity far above mosquito-borne fevers. Healthcare Costs & Policy: A new employer survey flags healthcare costs rising 9% in 2027 and pushing benefits changes, while radiology groups urge CMS to stop a proposed 50% pay cut for second services in the same visit. Global Outbreak Response: Congo has started Ebola vaccinations amid the fastest-growing outbreak, prioritizing frontline responders as funding gaps threaten containment. Clinical Trial Update: CARDIO-TTRansform reports eplontersen missed its primary endpoint in ATTR-CM despite strong transthyretin suppression. Care Access & Workforce: Radiology wait times are rising after Intermountain Health bought a private imaging practice, citing staffing shortages and a backlog. Digital Health & Workflows: A Japanese hospital pilot adds a one-click “like” button to radiology reporting to boost peer feedback and satisfaction. Industry & Markets: Shein’s IPO path highlights ongoing regulatory hurdles for China-linked firms, while U.S. marijuana companies eye exchange listings as federal banking barriers ease. Emergency Preparedness: Kansas County boosts EMS funding by 18.5%, adding ambulances and 15 full-time positions.

Cardiac Arrest Care: ICECAP trial results in JAMA found no neurological benefit from extending therapeutic hypothermia beyond 6 hours for comatose OHCA survivors. Aging-Informed Cardiology: An ACC scientific statement urges clinicians to factor cognition and frailty into cardiovascular care for older adults, shifting toward function-centered goals. Obesity & Costs: A study in Diabetes, Obesity and Metabolism reports Zepbound use in adults 55+ with obesity was linked to lower monthly healthcare costs over 12–18 months. COVID-19 Update: The FDA approved Pfizer-BioNTech’s 2026–2027 Comirnaty XFG formula for fall use, targeting the XFG variant. Neuroinflammation Pipeline: The FDA granted Fast Track to Cellenkos’ CK0803 Treg cell therapy for ALS after early phase 1/1b signals. ALS Drug Development: Tezspire’s Phase 3 win in EoE adds competitive pressure in a market dominated by Dupixent. Cybersecurity: FBI/DOJ disrupted a China-linked hacking group targeting hospitals and critical infrastructure. Rural Access: Premier expanded its partnership with Hospital Sisters Health System to boost performance and mission-driven care. Public Health Debate: New questions surround Pennsylvania’s “measles-associated” deaths after a county coroner’s findings complicated the state’s account. Healthcare Operations: AHA says AI tools can reduce provider admin burden without improperly increasing coding intensity.

Medicinal Plant Biotech: South African researchers are using plant tissue culture to conserve and commercialize indigenous medicinal species, aiming to turn biodiversity into new drug-discovery opportunities. Counterfeit Medicines Crackdown: Gujarat Police dismantled a multistate fake hypertension racket, seizing counterfeit Nicardia Retard 10 batches and arresting suspects after pharma complaints. Healthcare Investment: A new report finds healthcare is India’s second-largest private credit destination in H1 2026, driven by refinancing and expansion. Consumer Drug Platforms: An INVEST Digital Health panel spotlights how direct-to-consumer models are reshaping access, affordability, and adherence. AI in Drug Discovery: Huawei is partnering with Chinese drugmakers to speed medicine development using AI and machine learning. Global Pharma Moves: Novo Nordisk and AWS launched a co-innovation hub in London to compress drug discovery timelines with agentic AI. Clinical & Regulatory Updates: AstraZeneca’s Tezspire hit key goals in a late-stage trial for eosinophilic esophagitis, easing swallowing difficulty. Public Health Watch: Delhi reported 166 new H1N1 cases in 24 hours, prompting hospital preparedness reviews. Radiology Liability: A Radiology review highlights common malpractice patterns, with diagnostic errors dominating claims.

FDA Approvals: The FDA cleared Revolution Medicines’ Rasonque (daraxonrasib) as the first RAS-directed therapy for previously treated metastatic pancreatic cancer, after a phase 3 trial showed longer survival than standard chemo. The agency also expanded HIV care for kids, approving Tivicay PD (dolutegravir) for pediatric patients weighing at least 2 kg, and approved Tevimbra plus Ziihera with chemotherapy for first-line HER2+ gastric/gastroesophageal/esophageal adenocarcinoma. Cancer Diagnostics & Care Pathways: A European pilot study found AI-assisted nodule detection plus a navigator-tracked follow-up clinic helped catch early lung cancer from incidental CT findings. Healthcare Policy & Costs: The AHA urged CMS not to finalize outpatient payment changes that would accelerate 340B clawbacks and strain hospitals. A separate report says the Trump administration is preparing another round of Medicaid drug-pricing deals tied to “Most Favored Nation” discounts. Practice Operations & Regulation: STAT reports practice management deal volume is down sharply in 2026 amid tighter state oversight. Cybersecurity: Boston Scientific disclosed a cybersecurity incident disrupting IT systems and order processing. Behavioral Health Innovation: Onos Health raised $17M to expand an AI platform for behavioral health care pattern and gap analysis.

Sexual medicine meets emergency care: A new interview explores how emergency physicians can apply a whole-person, differential-diagnosis approach to sexual health concerns—often an early signal of broader physiologic and cardiovascular issues. AI in global health leadership: Qure.ai named Mihir Bhanushali EVP, Global Health, to expand AI-powered infectious-disease screening and care delivery across Africa, South Asia, Southeast Asia, and Latin America. Cardio drug pipeline at ESC: NewAmsterdam Pharma will present new obicetrapib data at the European Society of Cardiology Congress, targeting residual cardiovascular risk tied to LDL and Lp(a). Healthcare investing in India: Medicover India (backed by KKR) says it’s on track for profitability across its hospital network within 18 months, aiming for 20–25% margins. Wellness and hospital expansion: Piramal Alternatives plans a Rs 215 crore investment in Kolors Healthcare, while Park Medi World won a PPP mandate to build and run a 550-bed hospital in Prayagraj. Clinical research updates: ACCESS trial results suggest younger, more mismatched stem cell donors can perform as well as closely matched donors with post-transplant cyclophosphamide. Alzheimer’s diagnostics: FDA cleared Roche’s Alzheimer’s blood biomarker test for adults 55+, adding to the push for earlier detection. Safety and systems: DOJ opened a National Fraud Detection Center to benchmark billing data across programs, and a UK study found many neuroradiology second opinions reveal clinically meaningful discrepancies. Public health and disasters: Nepal’s flash floods killed at least eight and left hundreds missing; WHO is sending medicines and supplies. Cancer vaccine momentum: Coverage highlights late-stage melanoma results for an mRNA cancer vaccine plus Keytruda, signaling renewed confidence in cancer-vaccine platforms.